Stocks and Investing
Stocks and Investing
Fri, November 19, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Evan Seigerman Initiated (CADL) at Buy and Held Target at $18 on, Nov 19th, 2021
Evan Seigerman of BMO Capital, Initiated "Candel Therapeutics, Inc." (CADL) at Buy and Held Target at $18 on, Nov 19th, 2021.
Evan has made no other calls on CADL in the last 4 months.
There are 3 other peers that have a rating on CADL. Out of the 3 peers that are also analyzing CADL, 0 agree with Evan's Rating of Hold.
These are the ratings of the 3 analyists that currently disagree with Evan
- Chris Howerton of "Jefferies" Initiated at Strong Buy and Held Target at $22 on, Monday, August 23rd, 2021
- Colin Bristow of "UBS" Initiated at Strong Buy and Held Target at $9 on, Monday, August 23rd, 2021
- Judah Frommer of "Credit Suisse" Initiated at Buy and Held Target at $15 on, Monday, August 23rd, 2021
Contributing Sources